What does SYNERGIA MEDICAL do?

SYNERGIA MEDICAL is an IT company in Mont-Saint-Guibert. Public Limited, started on 26 September 2013, 1 establishment.

What is the address of SYNERGIA MEDICAL?

The registered office of SYNERGIA MEDICAL is located at Rue Emile Francqui 6, 1435 Mont-Saint-Guibert.

Is SYNERGIA MEDICAL still active?

Yes. According to the CBE (17 September 2026) SYNERGIA MEDICAL is active, legal situation “Normale toestand”, started on 26 September 2013.

Is SYNERGIA MEDICAL registered on Peppol?

Yes, SYNERGIA MEDICAL is registered on the Peppol network with ID 0208:0540563776.

What is the enterprise number of SYNERGIA MEDICAL?

The enterprise number of SYNERGIA MEDICAL is BE0540563776.

When was SYNERGIA MEDICAL founded?

SYNERGIA MEDICAL was founded on 26 September 2013.

Who are the directors of SYNERGIA MEDICAL?

According to the 2025 annual accounts, the directors of SYNERGIA MEDICAL are: Sophie Baratte, NEWTON BIOCAPITAL PARTNERS, DG INTERNATIONAL, TheClubDeal Capital Advisors SA, Sparaxis SA, Enrique Vega & Partners, Christian Boon-Falleur, CAPITAL & CROISSANCE.

Is SYNERGIA MEDICAL a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 26 September 2013; 5 annual accounts filed, latest fiscal year 2025; 11 directors known from the annual account.

How much profit did SYNERGIA MEDICAL make in 2025?

SYNERGIA MEDICAL recorded a loss after taxes of € 8,007,129 in financial year 2025.

What is the revenue of SYNERGIA MEDICAL?

As a small company, SYNERGIA MEDICAL is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -3,090,626.

How much does an employee at SYNERGIA MEDICAL earn?

The average wage cost per full-time employee at SYNERGIA MEDICAL was € 119,000 in 2025: staff costs of € 1.4 million for 11.7 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does SYNERGIA MEDICAL have?

According to the 2025 annual accounts, SYNERGIA MEDICAL has 11.7 full-time equivalents (FTE).

SYNERGIA MEDICAL (Public Limited) - Mont-Saint-Guibert

Dossier SYNERGIA MEDICAL, printed on 17 September 2026 from databakkes.be/en/0540563776/synergia-medical. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.
Shrinking team NBB

FTE fell two years in a row, from 21.7 to 11.7.
Figures corrected NBB

Corrected annual account filed for 2024.
Busy address KBO

18 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2025

SYNERGIA MEDICAL from Mont-Saint-Guibert, company number BE0540563776, closed financial year 2025 with a result of € -8 million after tax. For that financial year SYNERGIA MEDICAL recorded a gross margin of € -3.1 million and equity of € 3 million. Compared with financial year 2024, the result moved from € -6.2 million to € -8 million. The company made a loss. The buffer shrank hard: equity is 53 % below last year. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 24, 2026.

What it is worth Shrank hard

€ 3 million

▼ 53% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -8 million

▼ 30 % more loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 658,369

▼ 81% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -28.5 million.

People and assets in 2025

Full-time equivalents

11.7

▼ 6.4 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 1.4 million

▼ 23% vs 2024

€ 119,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 21,046

▼ 56% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 954,869

▼ 82% vs 2024

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 187,584

▼ 61% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 7,853

▼ 96% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ -893,284 Gross margin 2022: € -893,284 First fiscal year in the series	€ -1,297,061 Gross margin 2023: € -1,297,061 ▼ € 403,777 vs 2022 (€ -893,284) Unfavourable step	€ -115,656 Gross margin 2024: € -115,656 ▲ € 1.2 million vs 2023 (€ -1,297,061) Favourable step	€ -3,090,626 Gross margin 2025: € -3,090,626 ▼ € 3 million vs 2024 (€ -115,656) Unfavourable step	▼ € 3 million
Profit after taxes	€ -4,523,311 Profit after taxes 2022: € -4,523,311 First fiscal year in the series	€ -6,638,049 Profit after taxes 2023: € -6,638,049 ▼ € 2.1 million vs 2022 (€ -4,523,311) Unfavourable step	€ -6,156,385 Profit after taxes 2024: € -6,156,385 ▲ € 481,664 vs 2023 (€ -6,638,049) Favourable step	€ -8,007,129 Profit after taxes 2025: € -8,007,129 ▼ € 1.9 million vs 2024 (€ -6,156,385) Unfavourable step	▼ € 1.9 million
Equity	€ 18,576,968 Equity 2022: € 18,576,968 First fiscal year in the series	€ 11,826,090 Equity 2023: € 11,826,090 ▼ 36% vs 2022 (€ 18,576,968) Unfavourable step	€ 6,383,153 Equity 2024: € 6,383,153 ▼ 46% vs 2023 (€ 11,826,090) Unfavourable step	€ 3,013,591 Equity 2025: € 3,013,591 ▼ 53% vs 2024 (€ 6,383,153) Unfavourable step	▼ 53%
Total debts	€ 3,047,003 Total debts 2022: € 3,047,003 First fiscal year in the series	€ 4,756,612 Total debts 2023: € 4,756,612 ▲ 56% vs 2022 (€ 3,047,003) Unfavourable step	€ 7,792,210 Total debts 2024: € 7,792,210 ▲ 64% vs 2023 (€ 4,756,612) Unfavourable step	€ 2,712,746 Total debts 2025: € 2,712,746 ▼ 65% vs 2024 (€ 7,792,210) Favourable step	▼ 65%
Cash	€ 10,846,218 Cash 2022: € 10,846,218 First fiscal year in the series	€ 2,080,672 Cash 2023: € 2,080,672 ▼ 81% vs 2022 (€ 10,846,218) Unfavourable step	€ 3,475,631 Cash 2024: € 3,475,631 ▲ 67% vs 2023 (€ 2,080,672) Favourable step	€ 658,369 Cash 2025: € 658,369 ▼ 81% vs 2024 (€ 3,475,631) Unfavourable step	▼ 81%
Retained profit	€ -7,677,933 Retained profit 2022: € -7,677,933 First fiscal year in the series	€ -14,315,982 Retained profit 2023: € -14,315,982 ▼ € 6.6 million vs 2022 (€ -7,677,933) Unfavourable step	€ -20,472,367 Retained profit 2024: € -20,472,367 ▼ € 6.2 million vs 2023 (€ -14,315,982) Unfavourable step	€ -28,479,496 Retained profit 2025: € -28,479,496 ▼ € 8 million vs 2024 (€ -20,472,367) Unfavourable step	▼ € 8 million
Bank debt	€ 0 Bank debt 2022: € 0 First fiscal year in the series	€ 0 Bank debt 2023: € 0 Unchanged (€ 0) Unchanged	€ 5,315,114 Bank debt 2024: € 5,315,114 Unchanged (€ 0) Unfavourable step	€ 954,869 Bank debt 2025: € 954,869 ▼ 82% vs 2024 (€ 5,315,114) Favourable step	▼ 82%
Balance sheet total	€ 21,623,970 Balance sheet total 2022: € 21,623,970 First fiscal year in the series	€ 16,582,702 Balance sheet total 2023: € 16,582,702 ▼ 23% vs 2022 (€ 21,623,970) Unchanged	€ 14,581,965 Balance sheet total 2024: € 14,581,965 ▼ 12% vs 2023 (€ 16,582,702) Unchanged	€ 6,132,939 Balance sheet total 2025: € 6,132,939 ▼ 58% vs 2024 (€ 14,581,965) Unchanged	▼ 58%
Employees (FTE)	17.4 Employees (FTE) 2022: 17.4 First fiscal year in the series	21.7 Employees (FTE) 2023: 21.7 ▲ 4.3 vs 2022 (17.4) Unchanged	18.1 Employees (FTE) 2024: 18.1 ▼ 3.6 vs 2023 (21.7) Unchanged	11.7 Employees (FTE) 2025: 11.7 ▼ 6.4 vs 2024 (18.1) Unchanged	▼ 6.4

Key figures of SYNERGIA MEDICAL, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to SYNERGIA MEDICAL?

What happened at SYNERGIA MEDICAL in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2028 DG INTERNATIONAL stepped down as director. NBB
2028 TheClubDeal Capital Advisors SA stepped down as director. NBB
2028 CAPITAL & CROISSANCE stepped down as director. NBB
2028 Old Mill Invest SRL stepped down as director. NBB
2028 Aazaao SRL stepped down as director. NBB
Jul 24, 2026 New annual accounts for financial year 2025: loss of € 8 million. Source: NBB ↗
2025 CAPITAL & CROISSANCE became a director. NBB
2025 DG INTERNATIONAL became a director. NBB

In short

From € 4.5 million loss in 2022 to € 8 million loss in 2025.

Paid € 12,805 in corporate taxes since 2022.

Original PDFs at the National Bank ↗

A new publication or filing at SYNERGIA MEDICAL? We notify you, reason included.

Follow SYNERGIA MEDICAL

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

CHAGRAL INVEST 20.4%

Newton Biocapital I, pricaf privée de droit belge 14.6%

FEDERALE PARTICIPATIE- EN INVESTERINGSMAATSCHAPPIJ 12.5%

Wallonie Entreprendre 10.2%

The stake of CHAGRAL INVEST, Newton Biocapital I, pricaf privée de droit belge, FEDERALE PARTICIPATIE- EN INVESTERINGSMAATSCHAPPIJ, Wallonie Entreprendre, INVESTSUD TECH, B2START, SOCIETE D'INVESTISSEMENT ET DE FINANCEMENT DU BRABANT WALLON comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

SYNERGIA MEDICAL

The shares are held by CHAGRAL INVEST (20.4%), Newton Biocapital I, pricaf privée de droit belge (14.6%), FEDERALE PARTICIPATIE- EN INVESTERINGSMAATSCHAPPIJ (12.5%), Wallonie Entreprendre (10.2%), INVESTSUD TECH (5.9%) and B2START (2.9%).

See the full network in the app